How many Victoza biosimilars are approved?

Drug Landscape tracks 12 approved Victoza biosimilars across global regulators. 0 additional applications are filed and 1 are in Phase 3.

Is Victoza still patent-protected?

2 active patents remain on Victoza. Earliest expiry: 2037-01-09.

What is a biosimilar?

A biosimilar is a biological medicine highly similar to an already-approved reference biologic (the originator), with no clinically meaningful differences in safety, purity, or potency. Approved via abbreviated regulatory pathways once the originator's data exclusivity and patents expire.

Last reviewed 2026-06-10 · How we verify

Victoza biosimilars

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Complete Victoza (liraglutide) biosimilar landscape: 12 approved biosimilars, 0 filed, 1 in Phase 3. Sponsor, approval status, first approval date, and patent timeline for the originator.

12 approved 0 filed 1 Phase 3 2 active patents

About Victoza

Victoza (liraglutide) — originally marketed by Novo Nordisk. Class: GLP-1 Receptor Agonist [EPC]. Target: Glucagon-like peptide 1 receptor. Area: Metabolic.

Approved biosimilars (12)

Biosimilar	Sponsor	Phase
Liraglutide injection	Unidad de Cirugia Bariatrica Hospital Civil Dr. Juan I. Menchaca	marketed
Liraglutide combined with metformin	Sun Yat-sen University	marketed
"Liraglutide" and "Mitiglinide"	Third Affiliated Hospital of Third Military Medical University	marketed
liraglutide combined with orlistat	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	marketed
Liraglutide Pen Injector [Victoza]	Imperial College London	marketed
Liraglutide Pen Injector [Saxenda]	University College, London	marketed
Liraglutide and metformin	Peking University Third Hospital	marketed
Liraglutide+standard-of-care treatment	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed
Liraglutide + Orlistat	East Carolina University	marketed
Liraglutide + metformin	University Medical Centre Ljubljana	marketed
liraglutide monotherapy	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	marketed
Liraglutide + Exercise training	University of Virginia	marketed

Filed biosimilars under regulatory review (0)

No biosimilars currently under regulatory review.

Phase 3 biosimilars (1)

Biosimilar	Sponsor	Phase	First approval	Country
Liraglutide Pen Injector	University of North Carolina, Chapel Hill	phase 3

Originator patent timeline

Active patents (2)

2037-07-09 — 9968659*PED · Compound · US
2037-01-09 — 9968659 · Method of Use · US

Expired patents (2)

2026-02-13 — 8114833*PED · Compound · US
2025-08-13 — 8114833 · Formulation · US

Subscribe to biosimilar updates

Every regulatory action on Victoza or any of its biosimilars:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing